002287.SZ
Tibet Cheezheng Tibetan Medicine Co., Ltd. [002287.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002287.SZ Stock Summary
Top 10 Correlated Stocks
002287.SZ
In the News
002287.SZ Financial details
Company Rating
Buy
Market Cap
11.24B
Income
612.7M
Revenue
2.05B
Book val./share
-
Cash/share
-
Dividend
0.39
Dividend %
1.85%
Employees
2.97K
Optionable
No
Shortable
Yes
Earnings
28 Apr 2022
P/E
22.64
Forward P/E
-
PEG
7.46
P/S
5.96
P/B
3.18
P/C
-
P/FCF
35.72
Quick Ratio
2.08
Current Ratio
2.2
Debt / Equity
-
LT Debt / Equity
0.3
-
-
EPS (TTM)
1.16
EPS next Y
-
EPS next Q
-
EPS this Y
29.21%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
10.76%
Revenue last 5Y
7.83%
Revenue Q/Q
91.88%
EPS Q/Q
238.46%
-
-
-
-
SMA20
-4.55%
SMA50
5%
SMA100
-8.7%
Inst Own
-
Inst Trans
-
ROA
8%
ROE
14%
ROC
0.11%
Gross Margin
84%
Oper. Margin
29%
Profit Margin
26%
Payout
44%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
16.27-27.4
52W High
-15.85%
52W Low
+42%
RSI
52
Rel Volume
3.48
Avg Volume
1.38M
Volume
4.82M
Perf Week
5.92%
Perf Month
7.07%
Perf Quarter
-4.66%
Perf Half Y
-10.94%
-
-
-
-
Beta
0.629
-
-
Volatility
0.58%, 0.44%
Prev Close
6.37%
Price
22.72
Change
6.07%
002287.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.66 | 2.79 | 3.35 | 3.86 | 3.84 | |
| Net income per share | 0.69 | 0.76 | 1.35 | 0.89 | 1.15 | |
| Operating cash flow per share | 0.77 | 0.45 | 1.96 | 0.54 | 0 | |
| Free cash flow per share | 0.67 | -0.19 | 1.72 | 0.03 | 0 | |
| Cash per share | 2.61 | 3.44 | 3.5 | 3.73 | 0 | |
| Book value per share | 4.25 | 4.95 | 5.99 | 6.29 | 0 | |
| Tangible book value per share | 4.2 | 4.65 | 5.34 | 5.68 | 0 | |
| Share holders equity per share | 4.25 | 4.95 | 5.99 | 6.29 | 0 | |
| Interest debt per share | 0.57 | 2.32 | 2.85 | 3.31 | 0 | |
| Market cap | 11.49B | 13.71B | 16.16B | 12.12B | 11.96B | |
| Enterprise value | 10.44B | 13.08B | 16.94B | 13.37B | 0 | |
| P/E ratio | 31.54 | 33.93 | 22.57 | 25.65 | 19.56 | |
| Price to sales ratio | 8.19 | 9.29 | 9.12 | 5.93 | 5.85 | |
| POCF ratio | 28.3 | 57.43 | 15.61 | 42.41 | 0 | |
| PFCF ratio | 32.48 | -136.63 | 17.77 | 911.7 | 0 | |
| P/B Ratio | 5.12 | 5.24 | 5.1 | 3.63 | 0 | |
| PTB ratio | 5.12 | 5.24 | 5.1 | 3.63 | 0 | |
| EV to sales | 7.44 | 8.86 | 9.57 | 6.54 | 0 | |
| Enterprise value over EBITDA | 23.99 | 25.64 | 18.8 | 20.1 | 0 | |
| EV to operating cash flow | 25.72 | 54.83 | 16.37 | 46.82 | 0 | |
| EV to free cash flow | 29.52 | -130.43 | 18.63 | 1.01K | 0 | |
| Earnings yield | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | |
| Free cash flow yield | 0.03 | -0.01 | 0.06 | 0 | 0 | |
| Debt to equity | 0.13 | 0.46 | 0.46 | 0.51 | 0 | |
| Debt to assets | 0.1 | 0.27 | 0.26 | 0.29 | 0 | |
| Net debt to EBITDA | -2.4 | -1.22 | 0.87 | 1.89 | 0 | |
| Current ratio | 3.26 | 3.9 | 2.24 | 2.35 | 0 | |
| Interest coverage | 223.07 | 23.41 | 14.79 | 9.24 | 0 | |
| Income quality | 1.11 | 0.59 | 1.46 | 0.61 | 0 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.03 | 0 | |
| Payout ratio | 0.46 | 0.48 | 0.27 | 0.72 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.02 | 0.02 | 0.02 | 0 | |
| Research and developement to revenue | 0.04 | 0.04 | 0.04 | 0.03 | 0 | |
| Intangibles to total assets | 0.02 | 0.04 | 0.07 | 0.06 | 0 | |
| Capex to operating cash flow | -0.13 | -1.42 | -0.12 | -0.95 | 0 | |
| Capex to revenue | -0.04 | -0.23 | -0.07 | -0.13 | 0 | |
| Capex to depreciation | -1.45 | -7.78 | -1.91 | -3.27 | 0 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0 | 0 | 0 | |
| Graham number | 8.13 | 9.23 | 13.52 | 11.23 | 0 | |
| ROIC | 0.14 | 0.11 | 0.15 | 0.09 | 0 | |
| Return on tangible assets | 0.12 | 0.09 | 0.14 | 0.09 | 0 | |
| Graham Net | 2.28 | 1.54 | 0.07 | 0.33 | 0 | |
| Working capital | 1.48B | 2.21B | 1.63B | 1.83B | 0 | |
| Tangible asset value | 2.22B | 2.46B | 2.82B | 3.01B | 0 | |
| Net current asset value | 1.41B | 1.15B | 589.03M | 693.43M | 0 | |
| Invested capital | 0.13 | 0.46 | 0.46 | 0.51 | 0 | |
| Average receivables | 631.14M | 860.56M | 832.04M | 735.38M | 0 | |
| Average payables | 14.53M | 35.2M | 117.11M | 138.74M | 0 | |
| Average inventory | 61.14M | 78.2M | 106.45M | 123.14M | 0 | |
| Days sales outstanding | 178.66 | 255.79 | 129.79 | 150.16 | 0 | |
| Days payables outstanding | 40.88 | 88.66 | 253.11 | 105.26 | 0 | |
| Days of inventory on hand | 125.5 | 166.67 | 163.01 | 143.88 | 0 | |
| Receivables turnover | 2.04 | 1.43 | 2.81 | 2.43 | 0 | |
| Payables turnover | 8.93 | 4.12 | 1.44 | 3.47 | 0 | |
| Inventory turnover | 2.91 | 2.19 | 2.24 | 2.54 | 0 | |
| ROE | 0.16 | 0.15 | 0.23 | 0.14 | 0 | |
| Capex per share | -0.1 | -0.64 | -0.24 | -0.51 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.19 | 0.56 | 1.01 | 0.79 | 1.5 | |
| Net income per share | 0.21 | 0.18 | 0.41 | 0.13 | 0.44 | |
| Operating cash flow per share | 0.21 | 0.18 | 0.77 | -0.21 | 0 | |
| Free cash flow per share | 0.05 | 0.12 | 0.7 | -0.28 | 0 | |
| Cash per share | 3.73 | 4.09 | 5.28 | 4.29 | 0 | |
| Book value per share | 6.29 | 6.47 | 6.5 | 6.63 | 0 | |
| Tangible book value per share | 5.68 | 5.88 | 5.91 | 6.05 | 0 | |
| Share holders equity per share | 6.29 | 6.47 | 6.5 | 6.63 | 0 | |
| Interest debt per share | 3.22 | 3.45 | 3.95 | 4.02 | 0 | |
| Market cap | 12.12B | 13.35B | 12.67B | 13.8B | 11.96B | |
| Enterprise value | 13.37B | 15.01B | 14.15B | 15.69B | 0 | |
| P/E ratio | 26.84 | 35.99 | 14.43 | 50.54 | 12.88 | |
| Price to sales ratio | 19.27 | 45.12 | 23.73 | 33.13 | 14.97 | |
| POCF ratio | 107.35 | 143.95 | 31.07 | -126.42 | 0 | |
| PFCF ratio | 438.2 | 202.39 | 34.28 | -91.66 | 0 | |
| P/B Ratio | 3.63 | 3.9 | 3.68 | 3.93 | 0 | |
| PTB ratio | 3.63 | 3.9 | 3.68 | 3.93 | 0 | |
| EV to sales | 21.28 | 50.71 | 26.51 | 37.68 | 0 | |
| Enterprise value over EBITDA | 102.43 | 144.96 | 57.89 | 184.44 | 0 | |
| EV to operating cash flow | 118.5 | 161.78 | 34.71 | -143.8 | 0 | |
| EV to free cash flow | 483.74 | 227.46 | 38.29 | -104.27 | 0 | |
| Earnings yield | 0.01 | 0.01 | 0.02 | 0 | 0.02 | |
| Free cash flow yield | 0 | 0 | 0.03 | -0.01 | 0 | |
| Debt to equity | 0.51 | 0.53 | 0.6 | 0.6 | 0 | |
| Debt to assets | 0.29 | 0.3 | 0.32 | 0.33 | 0 | |
| Net debt to EBITDA | 9.64 | 15.98 | 6.06 | 22.29 | 0 | |
| Current ratio | 2.35 | 2.58 | 2.21 | 2.2 | 0 | |
| Interest coverage | 10.12 | 6.34 | 12.07 | 7.33 | 0 | |
| Income quality | 1 | 1 | 1.86 | -1.6 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0.01 | 0 | |
| Payout ratio | 0.01 | 0.04 | 0.03 | 3.02 | 0 | |
| Sales general and administrative to revenue | -0.1 | 0.12 | -0.03 | 0.26 | 0 | |
| Research and developement to revenue | 0.01 | 0.03 | 0.03 | 0.03 | 0 | |
| Intangibles to total assets | 0.06 | 0.06 | 0.06 | 0.06 | 0 | |
| Capex to operating cash flow | -0.76 | -0.29 | -0.09 | 0.38 | 0 | |
| Capex to revenue | -0.14 | -0.09 | -0.07 | -0.1 | 0 | |
| Capex to depreciation | -3.93 | -1.26 | -1.79 | 1.02 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.49 | 5.05 | 7.78 | 4.38 | 0 | |
| ROIC | 0.02 | 0.02 | 0.04 | 0.01 | 0 | |
| Return on tangible assets | 0.02 | 0.02 | 0.04 | 0.01 | 0 | |
| Graham Net | 0.33 | 0.75 | 0.98 | 0.37 | 0 | |
| Working capital | 1.83B | 1.97B | 2.1B | 1.83B | 0 | |
| Tangible asset value | 3.01B | 3.11B | 3.13B | 3.21B | 0 | |
| Net current asset value | 693.43M | 716.64M | 834.13M | 528.13M | 0 | |
| Invested capital | 0.51 | 0.53 | 0.6 | 0.6 | 0 | |
| Average receivables | 815.45M | 858.81M | 869.33M | 881.86M | 0 | |
| Average payables | 109.65M | 89.87M | 103.49M | 120.79M | 0 | |
| Average inventory | 132.41M | 141.31M | 154.26M | 158.74M | 0 | |
| Days sales outstanding | 120.43 | 266.53 | 145.36 | 194.83 | 0 | |
| Days payables outstanding | 73.64 | 136.26 | 149.62 | 166.61 | 0 | |
| Days of inventory on hand | 100.67 | 244.58 | 190.46 | 225.82 | 0 | |
| Receivables turnover | 0.75 | 0.34 | 0.62 | 0.46 | 0 | |
| Payables turnover | 1.22 | 0.66 | 0.6 | 0.54 | 0 | |
| Inventory turnover | 0.89 | 0.37 | 0.47 | 0.4 | 0 | |
| ROE | 0.03 | 0.03 | 0.06 | 0.02 | 0 | |
| Capex per share | -0.16 | -0.05 | -0.07 | -0.08 | 0 |
002287.SZ Frequently Asked Questions
What is Tibet Cheezheng Tibetan Medicine Co., Ltd. stock symbol ?
Tibet Cheezheng Tibetan Medicine Co., Ltd. is a CN stock and trading under the symbol 002287.SZ
What is Tibet Cheezheng Tibetan Medicine Co., Ltd. stock quote today ?
Tibet Cheezheng Tibetan Medicine Co., Ltd. stock price is $22.72 today.
Is Tibet Cheezheng Tibetan Medicine Co., Ltd. stock public?
Yes, Tibet Cheezheng Tibetan Medicine Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 1.38M
- Market Capitalization 11.24B
- Employee 2.97K
- CEO Mr. Kailie Liu
- Headquarters Nyingchi,CN
- IPO Date 2009-08-28
-
Website
https://www.cheezheng.com.cn 
Tibet Cheezheng Tibetan Medicine Co., Ltd. together with its subsidiaries, engages in the research, development, production, and sale of Tibetan medicine in China. It provides drug products in the areas of cardiovascular, respiratory, digestive, urinary and reproductive system, nervous system, musculoskeletal system, and gynecological disorders. The company was founded in 1995 and is based in Nyingchi, China. Tibet Cheezheng Tibetan Medicine Co., Ltd. operates as a subsidiary of Gansu Qizheng Industry Group Co., Ltd.
